Skip to content

Our mission

As a pioneer of highly-innovative precision radiotherapy products, BetaGlue’s mission is to bring easy-to-use and cost-effective life changing personalised treatment options for the benefit of solid tumour cancer patients worldwide.

For patients

YntraDose will provide life changing therapies

For interventional radiologists

YntraDose will provide an easy-to-use, safe and effective treatment option in the patient care pathway

For payers and healthcare providers

YntraDose will provide a resource-efficient and cost-effective treatment option

Our team

BetaGlue™ Therapeutics is led by a senior leadership team with more than a century of combined experience in growing companies and translating innovative oncology solutions through clinical trials and onto the market.

We are supported by an international board of directors with a strong track record of commercial success.

We are advised by globally recognised clinical Key Opinion Leaders in the fields of Interventional Radiology, Nuclear Medicine and Radiation Oncology from both Europe and the United States.

Leadership team

Dr. Colin Story

Chief Executive Officer (CEO)

Current Non-Executive Director of Hox Therapeutics & Advisory Board Member of UKI2S Fund

Co-founder of OxSonics & OrthoSon

Former CEO OxSonics & Hox Therapeutics

Former roles at GE Healthcare & Oxford University Innovation

Salvatore Calabrese

Chief Financial Officer (CFO)

+20 years of experience in the life sciences sector

Former CFO at Gain Therapeutics Inc. (NASDAQ: GANX)

Former CFO at Molmed S.p.A (MI: MLMD)

Former GM & Site Leader at Jazz Pharmaceutical SpA

Former CFO & COO at Gentium SpA (NASDAQ: GENT)

Pietro Bubba Bello

Head of Manufacturing & Operations

Former Site Head, Director of Operations, and Plant Director of Operations and HSE Country Manager at Novartis

Former Site Head and Qualified Person and Head of Quality Control at Advanced Accelerator Applications

Dr. Gianluca De Danieli MD, MSc

Head of Clinical Development

Former Medical Head, Italy and CEE at Advanced Accelerator Applications

Former Medical Lead, Fabry & Endocrinology Disease at Sanofi Genzyme

Former Medical Manager at Dompé and Medical Advisor at GE Healthcare

Gaia Bisaccioni

Head of RA/QA

Former Quality Site Head at Advanced Accelerator Applications

Former Quality Site Head & Deputy Qualified Person at Advanced Accelerator Applications

Dr. Pieter Janssen

Head of Product Development

20 years MedTech and Pharmaceutical R&D expertise at Johnson & Johnson, AstraZeneca, Novartis and Shire.

As CTO of VIPUN Medical successfully developed medical devices in compliance with MDR and FDA requirements.

Dr. Betty Polikar

Head of Clinical Operations

+ 25 years of experience in Clinical Development and Clinical Operations, during which different leading positions have been covered.

Formerly responsible for Start-Up Unit, Clinical Research Center of Excellence at Ospedale Pediatrico Bambino Gesù, Rome.

Formerly responsible for the Academic CRO of the Clinical Trial Center of the Fondazione Policlinico Gemelli, Rome.

Formerly responsible for strategic development pathways related to products (both drugs and medical devices) in different adult and pediatric indications.

Board of directors

Mike Cogswell


34 years of proven expertise in international healthcare leadership

Chairman of DermaCure RT & EbaMed SA

CEO & President of MagneTx Oncology Solutions Inc.

Managing Director of Mureva Phototherapy Inc.

Former SVP global sales ViewRay Inc., Mevion Medical Systems Inc. & Elekta Inc.

Mike Cogswell

Dr. Colin Story

Chief Executive Officer (CEO)

Current Non-Executive Director of Hox Therapeutics & Advisory Board Member of UKI2S Fund

Co-founder of OxSonics & OrthoSon

Former CEO OxSonics & Hox Therapeutics

Former roles at GE Healthcare & Oxford University Innovation

Dr. Michel Therin DVM, PhD

Independent Non-Executive Director

President of MT2 Consulting

Former President Advanced Therapies at Siemens Healthineers

Former Global Vice President at Medtronic Minimally Invasive Therapies Group

Giovanni Cerutti

Investor Nominee Director

CEO, NovaIcos, Immunotherapy for Life

30 years experience in commercial radiopharmaceuticals

Former Country Business Head, Advanced Accelerator Applications M.I. (Novartis)

Former Country Business Manager of GE HealthCare

Diana Saraceni

Investor Director (Panakès)

Co-founder and Managing Partner of Panakes Partners

Former Co-founder and Managing Partner at 360 Capital

Claudio Giuliano

Investor Director (Innogest)

Founder and CEO of Innogest Capital

Former Chairman of CV Committee at AIFI – the Italian Association of PE and VC

Former Vice President at Carlyle Group

Mike Maszy

Investor Nominee Director

25 years expertise in Operations, Engineering & New Product Development of Medical Devices

Former SVP Operations at Shockwave Medical (NASDAQ: SWAV)

Former VP Manufacturing at Endologix (NASDAQ: ELGX) & Trivascular (NASDAQ: TRIV)

Former leadership roles at Medtronic in Neurosurgery, Endovascular, Peripheral & Surgical Technologies

Mike Maszy

Clinical advisory board

Prof. Jafar Golzarian MD

Interventional Radiologist
Chairman of the advisory board

University of Minnesota Divisional Director IR & Vascular Imaging

Co-founder & President of GEST annual symposium

Prof. Jafar Golzarian

Prof. Luigi Solbiati MD

Interventional Radiologist

Professor of radiology at Huminatas University

Consultant radiologist at Huminatas Research Hospital

Performed the world’s first liver ablation in 1993

Luigi Solbiati

Prof. Roberto Iezzi MD

Interventional Radiologist

Associate Professor. Department of Radiology Universes Catolica

Director of Interventional Radiology at Policlinico Gemelli Rome

Roberto Iezzi

Prof. Govindarajan Narayanan MD

Interventional Radiologist

Chief of IR at Miami Cardiovascular & Miami Cancer Institutes

Course Director of the SPECTRUM IR oncology conference

Govindarajan Narayanan

Prof. Thomas Vogl MD

Interventional Radiologist

Director, Specialist in Radiology, University Hospital Frankfurt

Dr. Giulia Marvaso MD

Radiation Oncologist

Division of Radiotherapy, Istituto Europeo di Oncologia.

Assistant Professor Oncology and Onco-hematology Department, University of Milan.

Prof. Marco Maccauro MD

Nuclear Physician

Associate Professor, of Nuclear Medicine at University of Milan.

Associate Director of Nuclear Department at National Cancer Institute Milan.

Marco Macauro

Our values

We are opening new frontiers in radiotherapy

Pioneering earlier, effective treatments for patients in an accessible and impactful way.

Driven by Precision: Leading with Data and Passion

Our ethos combines data-driven analysis, determination, and a passion to redefine radiotherapy. By embracing these qualities, we ensure our approach is innovative, informed, and resilient, making every advancement a step towards excellence.

Upholding Integrity: Ethical Excellence as Our Standard

Ethics, professionalism, and transparency guide our every step, forming the bedrock of our interactions with each other, our partners, patients and stakeholders. This unwavering commitment to integrity drives us to new frontiers in radiotherapy, building trust and dignity in all we do.

Innovation with Purpose: Constantly Improving Patient Outcomes

Our dedication to innovation focuses on improving patient outcomes, making each breakthrough a leap towards more effective and compassionate care. We’re committed to not just advancing radiotherapy as a science, but ensuring these advancements directly benefit those we serve, ensuring access and availability wherever we can.

Compassion in Action: Fostering Empathy and Inclusivity

Our revolutionary efforts in radiotherapy are fuelled by empathy and the celebration of diversity. By prioritizing understanding and mutual respect, we are creating an environment where innovation is driven by a genuine desire to improve lives.

Our partners